---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-001706"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2022-01-04T23:59:59+00:00"
generated_at: "2026-06-27T20:51:53.981829+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alnylam promotes Dr. Akshay Vaishnaw to President; continues scientific leadership

## Summary
- Dr. Vaishnaw appointed President effective Jan 1, 2022; previously President of R&D.
- Receives $725,000 base salary, 60% target bonus, and $2M stock option grant vesting over 4 years.
- Yvonne Greenstreet named CEO effective same date; Vaishnaw to lead sustainable innovation in R&D.
- Vaishnaw has been at Alnylam since 2006; also serves on boards of Editas Medicine and Scholar Rock.

## SEC filing metadata
- accession: 0001193125-22-001706
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2022-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/d251998d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-001706
- JSON: https://secwatch.observer/filing/0001193125-22-001706.json
- Plain text: https://secwatch.observer/filing/0001193125-22-001706.txt

## Key facts
- Executive change
  Akshay K. Vaishnaw was appointed as President at ALNYLAM PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: President
  source text: On January 4, 2022, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Akshay K. Vaishnaw, M.D., Ph.D., the Company’s current President, Research and Development, as President effective January 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm
- Executive change
  Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: As previously announced, Yvonne L. Greenstreet, MBChB, MBA, the Company’s former President and Chief Operating Officer, was appointed Chief Executive Officer effective January 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.